Future Drug Pipelines And Prospects Revealed For RNAi Therapeutics
DUBLIN, Ireland --(Business Wire)-- Oct 20, 2008 Research and Markets (http://www.researchandmarkets.com/research/2b8231/the_future_of_rnai) has announced the addition of the "The Future of RNAi Therapeutics: Drug Pipelines and Prospects" report to their offering.
"The total RNAi therapy market is estimated to value $580m by 2012. This forecast is based upon current treatments, levels of market satisfaction and five new Phase II/III RNAi agents profiled in this report."
RNA interference continues to offer significant promise for a host of therapeutic treatments. Potentially any disease-causing gene, cell type or tissue can be targeted with RNAi, including those not ‘druggable' with small molecules or protein-based therapies. Pharma companies are increasingly investing in siRNA optimization or examining siRNA alternatives, in addition to staking out proprietary positions in lipid-based, nanotransporter-based and alternative delivery technologies. The development and licensing of such platforms will become crucial for developers over the coming years.
‘The Future of RNAi Therapeutics: Drug pipelines and prospects' is a report published by Business Insights that provides an in-depth assessment of recent progress and future opportunities for RNAi players in major therapeutic areas including infectious diseases, cancer, inflammation/immune dysfunction, CNS disorders and cardiology/metabolism.
The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary technologies and company pipelines, and the activities and strategies of 37 RNAi-based developers are profiled. This report also provides forecasts for market growth to 2012 across major RNAi market segments. Identify the developmental status of key RNAi agents, review the latest advances in RNAi technologies and assess the competitive landscape with this report's analysis of 37 companies across major therapeutic areas.
Measure the developmental progress of 97 RNAi agents, review the latest advances in delivery technologies and evaluate 37 RNAi-based companies across major therapeutic areas...
Use this report to...
- Analyze emerging RNAi agents and delivery technologies and examine new molecular targets and pipeline antisense drugs.
- Evaluate 97 RNAi compounds in development for infectious and inflammatory diseases, cancer and other major disease categories.
- Assess 37 competitors and potential collaborators developing RNAi technologies and examine the latest RNAi-related patenting trends.
- Identify potential growth segments and develop future strategies with this report's forecasts for the global RNAi therapy market to 2012.
Key findings...
- The total RNAi therapy market is forecast to reach a value of $580mn by 2012. This forecast is based upon current treatments, levels of market satisfaction and five new Phase II/III RNAi agents identified by Business Insights which are targeted at wet age-related macular degeneration, RSV infection and acute renal failure.
- Human proof-of-concept has been produced in a Phase 2 trial of an inhaled siRNA targeting respiratory syncytial virus (RSV). The trial returned a lower RSV infection rate, a greater number of subjects remaining infection-free and was well tolerated. At least 18 other anti-viral RNAi therapeutics are in commercial development.
- Therapeutic RNAi is being applied in cancer to target genes expressed during tumor development. There are 29 RNAi therapeutic cancer products currently in commercial development.
- At least 22 RNAi therapeutic products are in development for conditions involving pathological inflammation. The most advanced programs are in wet age-related macular degeneration.
- Sirna Therapeutics are the most prolific innovator in the field according to a Business Insights proprietary survey of over 2,000 RNAi-related patents and applications. Infectious diseases and cancer were found to be the main therapeutic applications claimed
Key Issues Examined by this Report...
- Targeting hard-to-treat diseases. RNAi represents a novel treatment approach for several conditions which are increasing in frequency and treatment difficulty, particularly certain viral infections, cancer, and chronic inflammatory diseases.
- Increasing competition. A number of recent developments in RNAi have intensified competition within the field. Leading companies have been submitting applications for specific RNAi targets, with Sirna Therapeutics seeking cover for over 250 mammalian and viral genes targeted by siRNA.
- Uncertainty over delivery platforms. There is a growing consensus that a single solution to the RNAi delivery problem is unlikely. Companies are currently optimizing nanotransporter and lipid-based mechanisms, while also investigating other modes.
- Intellectual property issues. RNAi companies derive current value from intellectual property, however with many patents appearing to overlap significantly, a litigious climate can be expected over the next few years as claims become contested.
Key Questions Answered...
- Which companies have technologies, products or collaborations focused on therapeutic RNAi?
- How is therapeutic RNAi being applied in cancer and infectious, inflammatory and other diseases?
- What approaches have been developed to activate RNAi for therapeutic purposes?
- What methods have been developed for optimizing siRNA design and delivery?
- What is the nature of the IP landscape in this area?
- What is the future outlook for the therapeutic RNAi market? <
Key Topics Covered:
- Introduction
- RNAi in infectious diseases
- RNAi in Cancer
- RNAi in inflammatory and other diseases
- RNAi Companies: Technologies and Therapies
- Market trends and opportunities
Companies Mentioned:
- Alnylam Pharmaceuticals Inc
- Ambrilia Biopharma Inc
- Angioblast Systems Inc
- AVI BioPharma Inc
- Benitec Ltd
- BioCancell Therapeutics Inc
- Calando Pharmaceuticals Inc
- Cequent Pharmaceuticals Inc
- Dicerna Pharmaceuticals Inc
- Generex Biotechnology Corp
- Genesis Research and Development Corp
- Green Cross Corp
- Gruenenthal Group
- Intradigm Corp
- Isis Pharmaceuticals Inc
- Lorus Therapeutics Inc
- MDRNA Inc
- Merck & Co Inc
- Nucleonics Inc
- Opko Health Inc
- ProNAi Therapeutics Inc
- Quark Pharmaceuticals Inc
- Regulus Therapeutics LLC
- Rosetta Genomics Ltd
- RXi Pharmaceuticals Corp
- Santaris Pharma A/S
- Senesco Technologies Inc
- Senetek plc
- Silence Therapeutics plc
- Sirnaomics Inc
- siRNAsense AS
- Stelic Institute & Co
- Targeted Genetics Corp
- Tekmira Pharmaceuticals Corp
- ToleroTech Inc
- Topigen Pharmaceuticals Inc
- TransDerm Inc
For more information visit http://www.researchandmarkets.com/research/2b8231/the_future_of_rnai
Copyright 2008 Business Wire All Rights Reserved